Archived Monthly Oncology Tumor Boards: Advances in Multidisciplinary Management of Acute Myeloid Leukemia
Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Systemic Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
The selection of systemic treatments in various lines of therapy for patients with metastatic castration-resistant prostate cancer (CRPC) has become more and more complicated over the last several years. Clinicians who work with patients with metastatic CRPC need to be educated on these updates so that they can help their patients make optimal treatment choices across lines of therapy.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Updates in Management of Renal Cell Carcinoma
Clinicians may find it difficult to determine which single- or multi-agent therapies are most effective for patients with different kidney cancer histologies and risk groups. The NCCN Categories of Preference and Categories of Evidence and Consensus help to stratify the most effective treatment regimens by histology and risk status.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Current and Emerging Systemic Therapies for Renal Cell Carcinoma: Clinical Evidence and Guideline Recommendations
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: Optimal Multidisciplinary Management of Advanced Esophageal Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.
Category
  • Gastric/Esophageal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Brain Metastases in Breast Cancer
Clinicians may be challenged when considering a trial of upfront systemic therapy alone for brain metastases, and a multidisciplinary discussion between medical and radiation oncology is recommended.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: New Options in Treatment of Relapsed/Refractory Multiple Myeloma
In order to optimize patient outcomes, clinicians need to understand the evidence behind the current recommendations in the guidelines, the rationale for appropriate treatment selection, management of any treatment- or MM-specific adverse events, and emerging strategies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Update on New Treatments for Biliary Tract Cancers
While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.
Category
  • Hepatobiliary Cancers
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Current and Emerging Systemic Therapies for Hepatocellular Carcinoma: Clinical Evidence and Guideline Recommendations
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with HCC.
Category
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages